Avella Specialty Pharmacy CEO shortlisted for Ernst & Young award
PHOENIX — Ernst & Young has named Avella Specialty Pharmacy founder and CEO John Musil as a finalist for a regional award.
Avella said Musil had been shortlisted for the Entrepreneur of the Year 2013 Award in the Mountain Desert region, which includes Colorado, Arizona and New Mexico. Avella is headquartered in Phoenix.
"I am honored to be a finalist for such a prestigious award," Musil said. "To be named the Ernst & Young Entrepreneur of the Year would be a tremendous achievement, but even being recognized as a finalist is incredible."
The company said the awards program recognizes high-growth entrepreneurs who demonstrate excellence and extraordinary success in areas including innovation, financial performance and personal commitment to their business and communities. Award winners will be announced at a special gala event on June 20 at the Denver Center for Performing Arts.
J&J plans slew of regulatory filings through 2017
NEW BRUNSWICK, N.J. — Johnson & Johnson expects to file for Food and Drug Administration approval of more than 10 new drugs over the next four years, the drug maker said Thursday.
J&J’s Janssen Pharmaceutical Cos. highlighted its more than 11 new product launches since 2009 and said it hoped to file with the FDA for more than two-dozen "significant" extensions to its branded drug lines by 2017.
"Our investment in transformational innovation has enabled strong growth that has allowed us to continue investing in our future portfolio," J&J chief scientific officer and worldwide chairman of the company’s pharmaceuticals group Paul Stoffels said. "With a steadfast focus on the most serious unmet medical needs, our approach is to identify the best science — internal and external — to deliver new options and solutions to patients."
The experimental drugs for which Janssen hopes to seek approval by 2017 include treatments for hepatitis C, cancers, autoimmune disorders, schizophrenia and new vaccines for flu, rabies and polio.
Kathy Ireland helps launch stem-cell derived beauty line
LOS ANGELES — Kathy Ireland, CEO and chief designer of Kathy Ireland Worldwide and women’s health advocate, is collaborating with board-certified surgeon Dr. David Scharp in bringing to the beauty market a stem cell-derived product brand called Stemáge.
They note that the unique aspect of the natural skin rejuvenation system is that it targets visible signs of aging through the proprietary use of human Mesenchymal stem cell derivatives, not stem cells but rather active ingredients or derivatives of which stem cells are comprised.
It is a first venture into the science of stem cells for Ireland. Her firm designs and markets more than 15,000 individual products throughout the world.
Available as a three-step skin rejuvenation system, Stemáge’s core active ingredient is a proprietary stem cell derivative called MDFc19, or Mesenchymal Derived Factor Complex 19. All of the ingredients found in Stemáge are either naturally sourced from botanicals and minerals or naturally produced biologically.
"Skin care is one of my passions. My work and my life were impacted by troubled skin. Stemáge is new, powerful and extraordinary. Expect to feel and see something different. Our relationship with the researchers and executive team at Stemáge is responsible for a strategic alliance between our two companies. Stem cells are the next phase of health and personal care. My skin feels healthier, trouble-free and finally, I’m able to wear less makeup. I love Stemáge. I believe you will too," stated Ireland, a “supermodel-turned-supermogul,” as described by Forbes magazine in a cover story.
The three-step system is comprised of:
- Nano Cleansing Gel with Nanosilver;
- Cellular Therapy Sérum; and
- Cellular Therapy Fluide.
The Stemáge collection includes additional products, such as:
- Cellular Therapy Eye Crème;
- Cellular Therapy Ultra-Hydratant Anti-Aging Concentrate Cellular Therapy Lip Sérum; and
- Cellular Therapy Whole Body Crème.